HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same

摘要

An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.

主权项

1. A method for the induction of a Wilms' tumor 1 (WT1)-specific cytotoxic T cell (CTL), comprising administering to an HLA-A*1101-positive subject an effective amount of
an isolated peptide consisting of the amino acid sequence selected from:(SEQ ID No: 5)Ser Ala Ser Glu Thr Ser Glu Lys Arg;(SEQ ID No: 6)Ser His Leu Gln Met His Ser Arg Lys,and(SEQ ID No: 7)Thr Gly Val Lys Pro Phe Gln Cys Lys.